NCT02301130 - Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 26, 2014

Primary Completion Date

December 8, 2017

Study Completion Date

March 5, 2018

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

mogamulizumab

Mogamulizumab will be administered intravenously (IV).

BIOLOGICAL

MEDI4736 (Durvalumab)

MEDI4736 will be administered intravenously (IV).

BIOLOGICAL

tremelimumab

Tremelimumab will be administered intravenously (IV).

Trial Locations (7)

Memorial Sloan-Kettering Cancer Center, New York

Georgia Cancer Center, Augusta

H. Lee Moffitt Cancer Center, Tampa

MD Anderson Cancer Center, Houston

The Angeles Clinic, Los Angeles

UCLA Hematology & Oncology Clinic, Los Angeles

Yale Cancer Center, New Haven